A PICO (Population, Intervention, Comparator, Outcome) is the structured question that defines what a Health Technology Assessment will judge. In the EU Joint Clinical Assessment, Member States set the PICOs, and because standards of care differ across Europe, one oncology submission can multiply into dozens of country-specific PICOs that the developer must all answer in the Annex I dossier within the 100-day clock.
If you are new to Health Technology Assessment, the single most important concept to understand about the EU Joint Clinical Assessment (JCA) is the PICO. It is what makes the JCA powerful, and what makes it hard.
What is a PICO?
PICO is a framework for asking a precise clinical question. It has four parts:
- Population (P): which patients (for example a line of therapy, histology or biomarker subgroup).
- Intervention (I): the new medicine being assessed.
- Comparator (C): what it is compared against, the relevant standard of care.
- Outcome (O): which results matter (overall survival, progression-free survival, quality of life, safety).
A PICO turns the question is this medicine good? into a specific, answerable research question. An assessment is only as relevant as its PICOs.
How PICOs work in the JCA
In the EU JCA, the Member States define the PICOs, not the company. During scoping, Member States submit the populations, comparators and outcomes that matter to them, and these are consolidated into the scope the company receives in the Commission's first request. The company cannot negotiate the PICOs; it must answer each one in full.
Why one submission becomes many questions
Here is the crux. Europe does not have a single standard of care. The medicine a patient would otherwise receive in one country may differ from another, because of national guidelines and reimbursement. So the same product, in the same indication, can attract different comparators in different countries, and each distinct comparator is, in effect, a new PICO.
Now add subpopulations. Oncology indications often split by line of therapy, histology or biomarker. Each clinically distinct subgroup can carry its own PICO. Multiply populations by comparators by outcome sets, and a single oncology submission can generate well into double digits of country-specific PICOs and hundreds of analyses.
The combinatorial PICO scope is the part everyone underestimates. One product, one indication, and a matrix of questions across up to 27 Member States.
The hard part: answering every PICO, on the clock
The developer must address every PICO in scope within the 100-day window (60 days if accelerated). Where head-to-head trial data against a country's comparator does not exist, which is common, the developer must build indirect treatment comparisons, such as network meta-analyses or matching-adjusted indirect comparisons. Miss a required PICO answer and the dossier fails the completeness check while the clock keeps running.
How to manage the PICO matrix
- Model every PICO per country as structured data, with its population, comparators and outcomes, not as prose buried in a document.
- Build a reusable evidence library so a study is captured once and reused across every PICO it supports.
- Track gaps per PICO: which can be answered with direct data, which need an indirect comparison, and which have no evidence.
- Keep one source of truth across Regulatory Affairs, HEOR and Biostatistics, with version history and an audit trail.
Built for the PICO-by-country matrix
JCA Studio models every country PICO as structured data, tracks evidence gaps per question and assembles the Annex I dossier, so the combinatorial scope stops being the thing that breaks your submission.
Request early access